Australian TGA Approves Medriva™ COVID-19 Rapid Antigen


SYDNEY, 09 Feb. 2022 (GLOBE NEWSWIRE) — The world’s leading provider of medical products ProcureNet has obtained clearance from the Australian Government to market and sell its Medriva COVID-19 Antigen Rapid Test Kit under ARTG #383819.

The Therapeutic Goods Administration (TGA) approval signaled a potential mass rollout of Medriva test kits to pharmacies and local governments, which allows for quick and easy detection via a nasal swab.

The green light for Medriva comes at a crucial time for Australians, as COVID-19 cases have remained high and Australia is set to open its borders to vaccinated tourists on February 21.

The Medriva COVID-19 Antigen Rapid Self-Test Kit is one of the most efficient on the market, with a 95% “sensitivity rate” and a 99% “relative specificity” rate. Its overall efficiency is 97%. The results meet performance standards recommended by the World Health Organization.

Founded in 2020 by Gurbaksh Chahal, Medriva had a successful launch thanks to its strong network of government partners, including organizations such as WHO, UNICEF, Health Canada, Italian Government, Hong Kong, Turkey, Sinovac and over a dozen states in the United States. .

“The TGA rigorously evaluated our antigen test kit for safety, quality and efficacy before it was provisionally registered for use in Australia,” commented Chahal, Managing Director of ProcureNet.

“The approval gives us the green light to provide the Medriva COVID-19 rapid antigen test kit to help Australians in their early detection of the virus. As countries begin to live with COVID-19, rapid tests for (MRT) are becoming the main tool to control any future outbreak. The complete elimination of the virus, through strict containment and quarantine measures, and its treatment as endemic are often seen as mutually exclusive strategies. The frequent adoption and widespread rapid home antigen testing could offer the best of both worlds, we look forward to helping Australians by bringing them the most cost-effective diagnostic solutions.”

Critics of RATs say that PCR is much more sensitive, but that can actually be a liability when it detects a residual amount of RNA during a decaying, non-infectious case. Data from a study by the UK COVID-19 Lateral Flow Monitoring Team shows that the sensitivity of RAT for contagious cases, even when asymptomatic, is typically around 97%. This means that with rapid tests, people who test positive can reliably know how many days to stay at home, while everyone else who tests negative can move on with their lives with confidence.

“Everything we do now is preparation for the next wave of variants or future pandemics. Self-testing is already as easy as other hygiene routines, like brushing your teeth. can be as cheap as a daily commute. When that happens, we can crush the pandemic with a new kind of ‘MRT’: mass rapid testing,” Chahal said.

The company’s global rise is a direct result of its strong social impact values ​​that have helped hundreds of millions of citizens across multiple continents fight COVID-19 through its vaccine and diagnostic products. The company will now expand its production capacity of 60 million rapid antigen test kits per month to the Australian market. Medriva also plans to make its cost-effective test kits available on Amazon.

Learn more about Medriva’s self-test kit:

About ProcureNet

ProcureNet is one of the world’s leading suppliers of pharmaceutical equipment and vaccine consumables. Medriva is the company’s B2B brand for its own consumable products.

Founded by serial entrepreneur Gurbaksh Chahal, the company connects government, international global organizations and major corporations to a vast network of pre-approved on-demand manufacturers who produce the world’s most sought-after products at fast speed and on a considerable scale. The rise of ProcureNet is driven by strong social impact values, as the company has provided life-saving medical equipment and supplies to aid in the treatment of COVID-19 during the most critical times of the pandemic.

Press contacts:
Euan Humphreys

Related Images

Image 1: Medriva COVID-19 Rapid Antigen Kit

Medriva COVID-19 Antigen Rapid Self-Test Kit

This content was posted through the press release distribution service on

  • Medriva COVID-19 Rapid Antigen Kit


Comments are closed.